Urinary enterolactone is associated with obesity and metabolic alteration in men in the US National Health and Nutrition Examination Survey 2001-10

British Journal of Nutrition

Volumn 113, Issue 4, 2015, Pages 683-690

  Xu, Cheng ^a,b   Liu, Qian ^a,b   Zhang, Qunwei ^c   Gu, Aihua ^a,b   Jiang, Zhao Yan ^d  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Nanjing Medical University   (China)

^c UNIVERSITY OF LOUISVILLE   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Enterolactone; Metabolic parameters; National Health and Nutrition Examination Survey; Obesity; Phyto oestrogens

Indexed keywords

CHOLESTEROL; DAIDZEIN; DRUG METABOLITE; ENTERODIOL; ENTEROLACTONE; EQUOL; GENISTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; O DESMETHYLANGOLENSIN; PHYTOESTROGEN; UNCLASSIFIED DRUG; 2,3-BIS(3'-HYDROXYBENZYL)BUTYROLACTONE; GAMMA BUTYROLACTONE; LIGNAN;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; BODY MASS; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; SEX DIFFERENCE; URINALYSIS; URINE LEVEL; WAIST CIRCUMFERENCE; ANALOGS AND DERIVATIVES; DOWN REGULATION; MIDDLE AGED; NUTRITION; SEXUAL DEVELOPMENT; STATISTICAL MODEL; UNITED STATES; URINE; YOUNG ADULT;

4-BUTYROLACTONE; ADOLESCENT; ADULT; AGE FACTORS; AGED; BODY MASS INDEX; CHILD; CROSS-SECTIONAL STUDIES; DOWN-REGULATION; FEMALE; HUMANS; LIGNANS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NUTRITION SURVEYS; OBESITY; PHYTOESTROGENS; SEX CHARACTERISTICS; UNITED STATES; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 84923625087     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114514004115     Document Type: Article

References (37)

1. Ogden CL, Carroll MD, Kit BK, et al. (2014) Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311, 806-814
2. Mokdad AH, Ford ES, Bowman BA, et al. (2003) Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289, 76-79
3. Collins S (2005) Overview of clinical perspectives and mechanisms of obesity. Birth Defects Res A Clin Mol Teratol 73, 470-471
4. Deshmukh-Taskar P, Nicklas TA, Morales M, et al. (2006) Tracking of overweight status from childhood to young adulthood: the Bogalusa Heart Study. Eur J Clin Nutr 60, 48-57
5. Ogden CL, Yanovski SZ, Carroll MD, et al. (2007) The epidemiology of obesity. Gastroenterology 132, 2087-2102
6. Newbold RR (2010) Impact of environmental endocrine disrupting chemicals on the development of obesity. Hormones (Athens) 9, 206-217
7. Yildiz F (2005) In Phytoestrogens in Functional Foods, pp. 3-5, 210-211. Boca Raton, FL: Taylor & Francis Limited
8. Lagari VS & Levis S (2013) Phytoestrogens in the prevention of postmenopausal bone loss. J Clin Densitom 16, 445-449
9. Adlercreutz H, Heinonen SM & Penalvo-Garcia J (2004) Phytoestrogens, cancer and coronary heart disease. Biofactors 22, 229-236
10. Penalvo JL & Lopez-Romero P (2012) Urinary enterolignan concentrations are positively associated with serum HDL cholesterol and negatively associated with serum triglycerides in U.S. adults. J Nutr 142, 751-756
11. Struja T, Richard A, Linseisen J, et al. (2014) The association between urinary phytoestrogen excretion and components of the metabolic syndrome in NHANES. Eur J Nutr 53, 1371-1381
12. Cole TJ, Bellizzi MC, Flegal KM, et al. (2000) Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 320, 1240-1243
13. National Institutes of Health&National Heart, Lung, and Blood Institute (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report. Obes Res 6, Suppl. 2, 51S-209S.
14. Alberti KG, Eckel RH, Grundy SM, et al. (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640-1645
15. Barnes S, Coward L, Kirk M, et al. (1998) HPLC-mass spectrometry analysis of isoflavones. Proc Soc Exp Biol Med 217, 254-262
16. Centers for Disease Control and Prevention (CDC) (2009) National Health and Nutrition Examination Surveys (NHANES 2003-04): Description of Laboratory Methodology: Urinary Phytoestrogens Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/data/nhanes/nhanes-03-04/l06phy-c-met.pdf (updated August 2009, cited
17. United States Department of Agriculture and United States Department of Health and Human Services (2010) Dietary Guidelines for Americans, 2010, 7th ed. Washington, DC: US Government Printing Office. http://www.health.gov/dietaryguidelines/dga2010/DietaryGuidelines2010.pdf
18. Morisset AS, Lemieux S, Veilleux A, et al. (2009) Impact of a lignan-rich diet on adiposity and insulin sensitivity in post-menopausal women. Br J Nutr 102, 195-200
19. Shi L, Ryan HH, Jones E, et al. (2014) Urinary isoflavone concentrations are inversely associated with cardiometabolic risk markers in pregnant U.S. women. J Nutr 144, 344-351
20. Liu ZM, Ho SC, Chen YM, et al. (2014) Whole soy, but not purified daidzein, had a favorable effect on improvement of cardiovascular risks: A 6-month randomized, doubleblind, and placebo-controlled trial in equol-producing postmenopausal women. Mol Nutr Food Res 58, 709-717
21. Frankenfeld CL, Atkinson C, Wahala K, et al. (2014) Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein. Eur J Clin Nutr 68, 526-530
22. Orgaard A & Jensen L (2008) The effects of soy isoflavones on obesity. Exp Biol Med (Maywood) 233, 1066-1080
23. Newbold RR, Padilla-Banks E & Jefferson WN (2009) Environmental estrogens and obesity. Mol Cell Endocrinol 304, 84-89
24. Bhathena SJ & Velasquez MT (2002) Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 76, 1191-1201
25. Yamori Y (2004) Worldwide epidemic of obesity: hope for Japanese diets. Clin Exp Pharmacol Physiol 31, Suppl. 2, S2-S4
26. Penza M, Montani C, Romani A, et al. (2006) Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. Endocrinology 147, 5740-5751
27. Keith SW, Redden DT, Katzmarzyk PT, et al. (2006) Putative contributors to the secular increase in obesity: exploring the roads less traveled. Int J Obes (Lond) 30, 1585-1594
28. Heindel JJ & vom Saal FS (2009) Role of nutrition and environmental endocrine disrupting chemicals during the perinatal period on the aetiology of obesity. Mol Cell Endocrinol 304, 90-96
29. Grun F & Blumberg B (2009) Endocrine disrupters as obesogens. Mol Cell Endocrinol 304, 19-29
30. Mense SM, Hei TK, Ganju RK, et al. (2008) Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environ Health Perspect 116, 426-433
31. Lampe JW (2003) Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J Nutr 133, Suppl. 3, 956S-964S
32. Cederroth CR, Vinciguerra M, Kuhne F, et al. (2007) A phytoestrogen-rich diet increases energy expenditure and decreases adiposity in mice. Environ Health Perspect 115, 1467-1473
33. Taxvig C, Specht IO, Boberg J, et al. (2013) Dietary relevant mixtures of phytoestrogens inhibit adipocyte differentiation in vitro. Food Chem Toxicol 55, 265-271
34. Cederroth CR, Vinciguerra M, Gjinovci A, et al. (2008) Dietary phytoestrogens activate AMP-Activated protein kinase with improvement in lipid and glucose metabolism. Diabetes 57, 1176-1185
35. Moutsatsou P (2007) The spectrum of phytoestrogens in nature: our knowledge is expanding. Hormones (Athens) 6, 173-193
36. Everard A & Cani PD (2013) Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol 27, 73-83
37. Hwang JT, Park IJ, Shin JI, et al. (2005) Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-Activated protein kinase. Biochem Biophys Res Commun 338, 694-699